<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478136</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10472</org_study_id>
    <nct_id>NCT04478136</nct_id>
  </id_info>
  <brief_title>Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?</brief_title>
  <official_title>Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study of 60 adult patients anticoagulated with
      bivalrudin for extracorporeal membrane oxygenation (ECMO). The study aims to identify the
      most precise early warning blood test or panel of blood tests to predict bleeding in patients
      on bivalrudin/ECMO. The project will involve comparing currently used blood tests with an
      extended panel of coagulation and metabolic blood tests with the aim of early warning of
      impending bleeding to allow intervention in the form of adjusted bivalrudin dose,
      modification of other risk factors, or transfusion with hemostatic products targeted to
      documented coagulation test abnormalities.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with changes in extended blood panel (EBP) for each of the bleeding and non-bleeding patient groups.</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>To determine if changes over time in an extended blood panel (EBP) and metabolic panel (MP) could provide early warning of impending bleeding in patients on ECMO.
The extended blood panel includes: Dilute thrombin time (DTT), Factor XIII, Factor VIII, Factor IX, and Von Willebrand Disease (VWD) panel, and Factor XI, Factor X, Factor VII, Factor V, Factor II, protein C, protein S, thromboelastogram (TEG), and TEG-platelet mapping).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants designated as major bleeders (MB)</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants designated as non-major bleeders (NMB)</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ECMO</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Major bleeders (MB)</arm_group_label>
    <description>Additional blood to be drawn from patients on ECMO who have a major bleeding event.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-major bleeders (NMB)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test of factor levels</intervention_name>
    <description>Blood draw from central line to check coagulation factors</description>
    <arm_group_label>Major bleeders (MB)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population in this prospective cohort study will include sixty (60) adults 18 - 70
        years who are AC with bivalirudin and placed on ECMO for cardiac and/or respiratory
        failure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults 18 - 70 years who are AC with bivalirudin and placed on ECMO for cardiac and/or
             respiratory failure. Surgical and non-surgical patients will be included.

        Exclusion Criteria:

          -  known pre-existing bleeding disorder (due to a factor deficiency that requires factor
             replacement, or platelet disorder), or a creatinine &gt; 2.0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiri Mackersey, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kiri Mackersey, MBChB</last_name>
    <phone>7189204187</phone>
    <email>kimacker@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheldon Goldstein, MD</last_name>
    <phone>7189204187</phone>
    <email>shgoldst@montefiore.org</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

